Furthermore, an upregulation in CD8+ T cells in immunologically deprived BCC and cSCC could be observed by the topical application of the immunomodulator imiquimod that activates the tumor microenvironment in the presentation of MHC-I molecules (13, 36). The gene discussed is CD8A; the disease is skin basal cell carcinoma.